A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants
← catalyst calendarNCT07588139 · readout in 15 d
Sponsored by Incyte Corporation (industry) · INCY — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
24estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-05-18 | actual | When the study began enrolling |
| Primary completion | 2026-09-03 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-09-19 | estimated | The whole study's end, after follow-up |
| First posted | 2026-05-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Participants
Interventions
- Drug: Povorcitinib — also filed as INCB054707
- Drug: Ruxolitinib
Primary outcomes
what the primary-completion date above is the date OFPharmacokinetics Parameter (PK): Cmax of dermal interstitial fluid (dISF) ruxolitinib
measured Up to Day 12
Pharmacokinetics Parameter: AUClast of dISF ruxolitinib
measured Up to Day 12
Pharmacokinetics Parameter: AUC∞ of dISF ruxolitinib
measured Up to Day 12
Pharmacokinetics Parameter: Cmax of dISF povorcitinib
measured Up to Day 12
Pharmacokinetics Parameter: AUClast of dISF povorcitinib
measured Up to Day 12
Pharmacokinetics Parameter: AUC∞ of dISF povorcitinib
measured Up to Day 12
Pharmacokinetics Parameter: Cmax of plasma ruxolitinib
measured Up to Day 12
Pharmacokinetics Parameter: AUClast of plasma ruxolitinib
measured Up to Day 12
Pharmacokinetics Parameter: AUC∞ of plasma ruxolitinib
measured Up to Day 12
Pharmacokinetics Parameter: Cmax of plasma povorcitinib
measured Up to Day 12
Pharmacokinetics Parameter: AUClast of plasma povorcitinib
measured Up to Day 12
Pharmacokinetics Parameter: AUC∞ of plasma povorcitinib
measured Up to Day 12
Permalink · INCY's whole pipeline · Catalyst calendar · Every registered study · What changed